NEUROSENSE THERAPEUTICS LTD (NRSN) Forecast, Price Target & Analyst Ratings

NASDAQ:NRSN • IL0011809592

Current stock price

0.83 USD
+0.07 (+9.21%)
At close:
0.7972 USD
-0.03 (-3.95%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEUROSENSE THERAPEUTICS LTD (NRSN).

Forecast Snapshot

Consensus Price Target

Price Target
$8.54
+ 929.22% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2025
EPS Estimate
-$0.12
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$8.54
Upside
+ 929.22%
From current price of $0.83 to mean target of $8.54, Based on 10 analyst forecasts
Low
$3.03
Median
$8.42
High
$14.70

Price Target Revisions

1 Month
-17.62%
3 Months
-17.62%

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for NRSN. The average price target is 8.54 USD. This implies a price increase of 929.22% is expected in the next year compared to the current price of 0.83.
The average price target has been revised downward by 17.62% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

NRSN Current Analyst RatingNRSN Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

NRSN Historical Analyst RatingsNRSN Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
82.00%
NRSN was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about NRSN.
In the previous month the buy percentage consensus was at a similar level.
NRSN was analyzed by 10 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-25D. Boral CapitalMaintains Buy -> Buy
2026-03-17D. Boral CapitalMaintains Buy -> Buy
2026-03-10Roth CapitalInitiate Buy
2026-03-09D. Boral CapitalMaintains Buy -> Buy
2025-12-22D. Boral CapitalMaintains Buy -> Buy
2025-11-24D. Boral CapitalMaintains Buy -> Buy
2025-08-15D. Boral CapitalMaintains Buy -> Buy
2025-07-10D. Boral CapitalMaintains Buy -> Buy
2025-05-12D. Boral CapitalInitiate Buy
2024-12-16Maxim GroupDowngrade Buy -> Hold
2023-07-17Alliance Global PartnersInitiate Buy
2022-01-07Maxim GroupInitiate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2025
EPS Estimate
-$0.12
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
-6.64%
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-109.09%
EPS (3 Months)
-109.09%

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2025 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
NRSN revenue by date.NRSN revenue by date.
N/AN/AN/A
583.67%		N/A
234.16%		N/A
1,348.97%		N/A
227.79%		N/A
74.76%		N/A
19.70%		N/A
4.60%
EBITDA
YoY % growth
NRSN ebitda by date.NRSN ebitda by date.
-1.24M-2.89M
-133.06%		-5.59M
-93.43%		-13.46M
-140.79%		-12.028M
10.64%		-9.88M
17.86%		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
NRSN ebit by date.NRSN ebit by date.
-1.24M-2.89M
-133.06%		-5.59M
-93.43%		-13.55M
-142.40%		-12.049M
11.08%		-9.902M
17.82%		N/A
-13.43%		N/A
-5.62%		N/A
2.90%		N/A
13.63%		N/A
1,734.12%		N/A
284.46%		N/A
80.15%		N/A
20.52%		N/A
4.64%
Operating Margin
NRSN operating margin by date.NRSN operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
NRSN eps by date.NRSN eps by date.
N/AN/AN/AN/AN/A-0.54
37.72%		N/A
27.28%		N/A
28.57%		N/A
18.18%		N/A
-11.11%		N/A
1,320.00%		N/A
102.95%		N/A
64.46%		N/A
20.04%		N/A
4.26%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.12
-6.64%		-0.11
-75.66%		0.00
100.00%		-0.20
-2.63%		0.00
100.00%		-0.18
-74.20%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-2.678M
-27.08%		-3.876M
60.86%		N/A-5.967M
-27.17%		N/A-6.885M
-77.63%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

NRSN Yearly Revenue VS EstimatesNRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NRSN Yearly EPS VS EstimatesNRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6 8 10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
16.35%
EPS Next 5 Year
50.66%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

NEUROSENSE THERAPEUTICS LTD / NRSN Forecast FAQ

What do analysts expect the price target to be for NEUROSENSE THERAPEUTICS LTD (NRSN)?

10 analysts have analysed NRSN and the average price target is 8.54 USD. This implies a price increase of 929.22% is expected in the next year compared to the current price of 0.83.

What are the consensus estimates for NRSN stock next earnings?

The consensus EPS estimate for the next earnings of NEUROSENSE THERAPEUTICS LTD (NRSN) is -0.12 USD and the consensus revenue estimate is 0 USD.

What is the consensus rating for NEUROSENSE THERAPEUTICS LTD (NRSN) stock?

The consensus rating for NEUROSENSE THERAPEUTICS LTD (NRSN) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.